Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 4
1996 3
1997 4
1998 3
1999 10
2000 8
2001 7
2002 10
2003 3
2004 6
2005 3
2008 2
2014 1
2020 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Buchdunger E, Trinks U, Mett H, Regenass U, Meyer T, McGlynn E, Pinna LA, Traxler P, Lydon NB, Zimmermann J. Buchdunger E, et al. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12069. doi: 10.1073/pnas.95.20.12069-a. Proc Natl Acad Sci U S A. 1998. PMID: 9786782 Free PMC article. No abstract available.
Author errata.
Lydon N, Mett H, Mueller M, Becker M, Cozens RM, Daniels D, Traxler P, Buchdunger E, Stover D. Lydon N, et al. Among authors: buchdunger e. Int J Cancer. 1999 May 17;81(4):669. doi: 10.1002/(sici)1097-0215(19990517)81:4<669::aid-ijc27>;2-c. Int J Cancer. 1999. PMID: 10336342 Free article. No abstract available.
Pharmacology of imatinib (STI571).
Buchdunger E, O'Reilly T, Wood J. Buchdunger E, et al. Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36. doi: 10.1016/s0959-8049(02)80600-1. Eur J Cancer. 2002. PMID: 12528770 Review.
Imatinib: a selective tyrosine kinase inhibitor.
Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J. Manley PW, et al. Among authors: buchdunger e. Eur J Cancer. 2002 Sep;38 Suppl 5:S19-27. doi: 10.1016/s0959-8049(02)80599-8. Eur J Cancer. 2002. PMID: 12528769 Review.
Bcr-Abl inhibition as a modality of CML therapeutics.
Buchdunger E, Matter A, Druker BJ. Buchdunger E, et al. Biochim Biophys Acta. 2001 Aug 31;1551(1):M11-8. doi: 10.1016/s0304-419x(01)00022-1. Biochim Biophys Acta. 2001. PMID: 11553417 Review. No abstract available.
Tyrosine kinase inhibitors: from rational design to clinical trials.
Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J. Traxler P, et al. Among authors: buchdunger e. Med Res Rev. 2001 Nov;21(6):499-512. doi: 10.1002/med.1022. Med Res Rev. 2001. PMID: 11607931 Review.
64 results